Nascent Biotech, Inc. Stock Other OTC
Equities
NBIO
US63108Q1013
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 1 | Sales 2023 | - | Capitalization | 7.16M |
---|---|---|---|---|---|
Net income 2022 | - | Net income 2023 | -2M | EV / Sales 2022 | 6,213,671 x |
Net cash position 2022 | 94.41K | Net Debt 2023 | 217K | EV / Sales 2023 | - |
P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-2.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 103B | |
+1.41% | 95.71B | |
-0.20% | 22.02B | |
-17.84% | 20.9B | |
-9.12% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |